| Identification | Back Directory | [Name]
PLpro inhibitor | [CAS]
1093070-14-4 | [Synonyms]
PLpro inhibitor
5-acetamido-2-methyl-n-(2-naphthalen-1-ylethyl)benzamide
5-acetamido-2-methyl-N-[2-(1-naphthalenyl)ethyl]benzamide
5-(acetylamino)-2-methyl-N-[(1R)-1-(1-naphthalenyl)ethyl]-
5-acetylamino-2-methyl-N-[(R)-1-(1-naphthyl)ethyl]benzamide
5-Acetylamino-2-methyl-N-(1R-naphthalen-1-yl-ethyl)benzamide
5-(Acetylamino)-2-methyl-N-[(1R)-1-(1-naphthalenyl)ethyl]benzamide
BENZAMIDE; 5-(ACETYLAMINO)-2-METHYL-N-[(1R)-1-(1-NAPHTHALENYL)ETHYL]- | [Molecular Formula]
C22H22N2O2 | [MDL Number]
MFCD12547684 | [MOL File]
1093070-14-4.mol | [Molecular Weight]
346.42 |
| Chemical Properties | Back Directory | [Boiling point ]
584.7±50.0 °C(Predicted) | [density ]
1.189±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml | [form ]
Powder | [pka]
14.13±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 μM[1]. PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 μM and an EC50 of 21.0 μM[2]. | [Definition]
ChEBI: KOM70144 is a benzamide that is GRL-0617 in which one of the hydrogen's of the primary amino group is replaced by an acetyl group. It an inhibitor of SARS-CoV and SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 2.6 muM and 5.0 muM, respectively. It also inhibits SARS-CoV and SARS-CoV-2 infection of Vero E6 cells in vitro (EC50 values are 13.1 and 21 muM, respectively). It has a role as a protease inhibitor and an anticoronaviral agent. It is a member of naphthalenes, a member of benzamides, a secondary carboxamide and a member of acetamides. It is functionally related to a GRL-0617. | [storage]
Store at -20°C | [References]
[1] Ratia, K., et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24. DOI:10.1073/pnas.0805240105
[2] http://www.google.com/patents/WO2010022355A1cl=en
[3] Brendan T Freitas, et al. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS Infect Dis. 2020 May 19. DOI:10.1021/acsinfecdis.0c00168 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|